ATP5PD

Across TCGA pan-cancer cohorts, ATP5PD RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of ATP5PD’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ATP5PD RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ATP5PD is over-expressed in tumor, although a few such as THCA and COAD show the opposite, repressed pattern.

LIHC, LUAD, and LUSC are the cancer types where ATP5PD tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATP5PD RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	All	+0.956	<.001	9	view →
LUAD	All	III,IV	+0.565	<.001	9	view →
LUSC	All	II,III,IV	+0.566	<.001	6	view →
BRCA	All	III,IV	+0.537	<.001	6	view →
CHOL	All	All	+0.871	<.001	5	view →
BLCA	All	All	+0.295	.003	5	view →
THCA	All	All	−0.259	.003	5	view →
COAD	All	All	−0.337	.006	4	view →
KICH	Female	All	−0.624	.005	3	view →
KIRP	All	II,III,IV	+0.371	.010	3	view →
READ	All	All	−0.359	.008	2	view →
UCEC	All	All	+0.327	.023	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

ATP5PD–LIHC

Open the LIHC breakdown →